ii) subsequent establishment ofa screening system for HIV-1 protease inhibitors from microbial metabolite origin by using the expressed protease and a peptide analogous to one of the HIV-1 polyproteins; and iii) a novel screening system of naturally-occurring protease inhibitors by using E. coli carrying the recombinant plasmid. Finally, a comparison of the two screening systems is madeand their advantages are discussed.
A DNAfragment carrying synthetic HIV-1 protease was obtained from plasmid BBG40 (British Biotechnology Laboratory), inserted into an expression vector pKP1500, and expressed in E. coli KP39981O).
The construction of a recombinant plasmid pMAK105 is illustrated in Fig. 1 . The HIV-1 protease-coding fragment was excised from the APR. 1994 BBG 40 by a double digestion with EcoRl and Hindlll, and amplified by PCR using 17-mer primer 16-mer primer (primer 2: 5 -ATATAAGCTTTTAC-TA-3')-The primers 1 and 2 were designed to meet the following conditions: Original restriction sites, EcoKl and Hindlll, could be changed into Hindlll and EcoRl, respectively, so that the protease gene could be inserted in a proper orientation into the expression vector; and at the same time, with the primer 1, ll-base pairs could be retained between the plausible SD sequence (-AGGA-) of the pKP1500 and the initiation codon (-ATG-) of the protease gene for a higher rate of transcription on the resulting plasmid. The PCRproduct was digested with the two restriction endonucleases, purified, and ligated to pKP1500 to construct the plasmid pMAK105.The synthetic HIV-1 protease gene was located down-stream from the tac promoter, thus making it possible for the protease gene to be expressed upon induction by isopropyl-jS-thiogalactopyranoside (IPTG). The HIV-1 protease was partially purified from the protease-expressed E. coli by a modified methed of Strickler et a/.ll).
The HIV-1 protease activity was determined by using the heptapeptide as a substrate (Ser-Gln-AsnTyr-Pro-Ile-Val), which mimics the cleavage site of the polyprotein (pl7/p24) as it originated in HIV-1.
The reaction mixture consists of: lOOmM of MES (pH 5.5); 0.2mM of the peptide substrate; 2.0m of NaCl; and the partially purified protease. The reaction was performed at 37°C for 20 minutes, and terminated by exposure in boiling water for 3 minutes; and the reaction mixture was centrifuged at 12,000rpm for 5 minutes, and the supernatant was subjected to reverse phase HPLCfor quantification of the remaining undigested peptide. An ODS-120T column (0.6 x 15cm, Tosoh) was equilibrated in 23% acetonitrile and 0.1% TFA at a flow rate of 1.0 ml/minute. The effluent was monitored by photometric absorbance at 214nm. Normally, the undigested peptide was eluted at a retention time of 6.0 minutes. Weobserved that the substrate was digested at the same site as expected from the literature5), thus confirming that the HIV-1 protease was correctly expressed in E. coli (Fig. 2) . The enzyme unit (u) was defined as the amount of the enzyme preparation which cleaves 1 mmolof the substrate for 1 minute: One ml of the cell lysate prepared in this study contained approximately 1 find protease inhibitors from microbial metabolites:
The reaction condition was the sameas described above except that 0.24u of the enzymepreparation and 4jA of a test microbial culture were contained in 40 [A of the reaction mixture. Inhibition rate was calculated by measuring decrease of peak areas derived from the heptapeptide on the HPLCchromatograms as seen in Fig. 2 . With this screening system, we isolated a new HIV-1 protease inhibitor, Mer-N5075A, as reported previously12).
During the expression study, we found that the growth of the recombinant E. coli was inhibited by the protease expressed within the cells. The E. coli cells (1 x 104CFU/ml) were incubated at 37°C for 18 hours in the medium consisting of: 3.2% glucose, 1.0% yeast extract (Difco), and 0.5% NaCl (pH 7.2) in the presence or the absence of 0.01 mMof IPTG. The cell growth was monitored by photometric measurement at 630nm. The addition of IPTG caused a strong growth inhibition in the pMAK105-bearing E. coli cells, but did not in both pKP1500-bearing cells and the E. coli alone ( Table  1 ). The results suggested that the expressed HIV-1 protease was lethal to the host cells presumably by cleaving their intracellular proteins. A similar observation was reported as well13).
It was expected that if some HIV-1 protease inhibitor successfully penetrated cells and inhibited effectively the intracellularly-expressed protease, the cells could grow normally in the presence of such a protease inhibitor. A highly-specific HIV-1 protease inhibitor, Ro31-89591}, was used to examine this E. coli harboring PMAK105 was incubated under the sameconditions as described above except for the addition of increasing concentrations of the inhibitor. be screened by photometrically monitoring the growth difference of the recombinant E. coli in the presence and the absence of IPTG (called OD method hereafter). Table 3 shows the results of comparison of IC50 values of the three protease inhibitors with both the ODand the HPLCmethods. Ro31-8959 was proven to be a specifically-active inhibitor, however, the OD method required a 430-fold higher concentration of the inhibitor than the HPLCmethod: One of the possible reasons for this is due to a poor penetration of the inhibitor into E. coli. Similar results were obtained with pepstatin and a-MAPI. Although the ODmethod needs a higher concentration of test compounds, it seems to have the following advantages: high throughput; moderate cost; and high potential to identify low-molecular weight inhibitors. In our current screening the ODand the HPLCmethods have been employed as primary and secondary screenings, respectively.
As a result, we have isolated several potent HIV-1 protease inhibitors form microbial metabolites, VOL.47 NO.4 THE JOURNAL OF ANTIBIOTICS which will be published elsewhere.
